Alpha Cognition Inc (ACOG) Stock Analysis & Investment Frameworks
Alpha Cognition Inc (ACOG) stock analysis on Invetso. Review Alpha Cognition Inc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Alpha Cognition Inc Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Alpha Cognition Inc Key Financial Metrics
- Market Cap: $127.98M
- Revenue: $10.22M
- ROE: -45.33%
- ROIC: -50.04%
- Dividend Yield: N/A
About Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Alpha Cognition Inc Investment Frameworks
Invetso analyzes Alpha Cognition Inc (ACOG) across the following frameworks:
- Alpha Cognition Inc 10Y Growth Potential
- Alpha Cognition Inc Scenario Analysis
- Alpha Cognition Inc Risks & Opportunities
- Alpha Cognition Inc Economic Moat
- Alpha Cognition Inc Business Model
- Alpha Cognition Inc Management
- Alpha Cognition Inc SWOT Analysis
- Alpha Cognition Inc Porter's 5 Forces
- Alpha Cognition Inc PESTLE Analysis
- Alpha Cognition Inc ESG Analysis